COVID-19 Vaccine Studies
In 2020, the world faced an unprecedented global pandemic. As the COVID-19 virus quickly spread across states, nations, and continents, time was a critical factor. Humanity needed to develop a vaccine for this virus faster than had ever been done before.
To date, ClinChoice has supported thirteen COVID-19 vaccine studies, comprised of over 148,000 total patients across seven countries. ClinChoice has helped sponsors overcome the unique challenges and complexities presented by COVID-19 trials with innovative strategies and technologies for faster, more accurate data capture and analysis. We understand the importance of having a team you can depend on, and our solutions include access to industry professionals with hands-on COVID-19 experience.
When it comes to COVID-19 trials, speed is often a necessity. Our teams work tirelessly to ensure key deliverables are met in increasingly challenging timelines with the utmost dedication and collaboration. We constantly go above and beyond to raise the standard of excellence in supporting clinical trials for COVID-19. Our teams are committed to contributing to a healthier and safer world by accelerating the development and commercialization of COVID-19 vaccines and innovative treatments.
By the numbers
Studies conducted or ongoing with four vaccine candidates
More than 148,000 Patients enrolled to date
More than 460 collaborations with sites in seven countries
Regulatory submissions, incl. US, UK, EMA, Canada, South Africa, Argentina, Brazil, India, WHO
Studies conducted or ongoing in treatment protocols and/or observational research
More than 15,115 Patients enrolled to date
More than 516 collaborations with sites in seven countries
More than 50 Countries in NA, EU, APAC, and LATAM